Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYE National Vision	$22.95 -1.2%	$23.68	$9.56 ▼ $25.67	$1.84B	1.27	2.17 million shs	1.38 million shs
LMAT LeMaitre Vascular	$95.81 +0.7%	$84.32	$71.42 ▼ $109.58	$2.15B	0.79	161,243 shs	192,316 shs
NVCR NovoCure	$11.59 -0.3%	$15.42	$10.87 ▼ $34.13	$1.30B	0.61	2.24 million shs	1.41 million shs
RXST RxSight	$8.22 -1.1%	$10.47	$6.32 ▼ $58.23	$340.01M	1.16	1.16 million shs	993,401 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYE National Vision	-1.16%	-5.05%	-9.14%	+19.41%	+119.62%
LMAT LeMaitre Vascular	+0.69%	+1.64%	+16.51%	+13.02%	+16.77%
NVCR NovoCure	-0.47%	+0.70%	-30.97%	-35.22%	-33.77%
RXST RxSight	-1.08%	+5.52%	+10.34%	-42.07%	-83.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYE National Vision	2.6651 of 5 stars	2.3	2.0	0.0	3.3	3.3	0.0	0.0
LMAT LeMaitre Vascular	1.9559 of 5 stars	1.3	2.0	3.3	0.0	2.1	2.5	1.3
NVCR NovoCure	3.9999 of 5 stars	3.3	2.0	0.0	4.5	1.9	3.3	0.0
RXST RxSight	1.4921 of 5 stars	3.0	1.0	0.0	0.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYE National Vision	2.60	Moderate Buy	$24.73	7.74% Upside
LMAT LeMaitre Vascular	2.50	Moderate Buy	$98.00	2.29% Upside
NVCR NovoCure	2.57	Moderate Buy	$28.79	148.37% Upside
RXST RxSight	1.91	Reduce	$10.00	21.65% Upside

Current Analyst Ratings Breakdown

Latest RXST, NVCR, LMAT, and EYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
8/8/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00
8/8/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $11.00
8/7/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $22.00
8/7/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$24.00 ➝ $27.00
8/7/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
8/6/2025	LMAT LeMaitre Vascular	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$92.00 ➝ $95.00
8/6/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$95.00
7/30/2025	EYE National Vision	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
7/25/2025	NVCR NovoCure	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$40.00 ➝ $14.50
7/23/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $24.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYE National Vision	$1.82B	1.00	$1.62 per share	14.19	$10.74 per share	2.14
LMAT LeMaitre Vascular	$219.86M	9.87	$2.41 per share	39.83	$16.02 per share	5.98
NVCR NovoCure	$605.22M	2.14	N/A	N/A	$3.13 per share	3.70
RXST RxSight	$139.93M	2.40	N/A	N/A	$6.79 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYE National Vision	-$28.50M	-$0.18	N/A	85.00	2.74	-0.75%	3.56%	1.49%	N/A
LMAT LeMaitre Vascular	$44.04M	$2.06	46.51	44.15	2.45	20.08%	13.67%	9.14%	10/30/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.56	N/A	N/A	N/A	-27.13%	-47.74%	-13.79%	10/29/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.80	N/A	N/A	N/A	-21.93%	-11.56%	-10.31%	N/A

Latest RXST, NVCR, LMAT, and EYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Guidance Update	RXST RxSight	-$0.04	-$0.08	-$0.04	-$0.29	$39.78 million	$33.64 million
8/6/2025	Q2 2025	EYE National Vision	$0.12	$0.18	+$0.06	$0.11	$469.21 million	$486.42 million
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	$0.60	+$0.03	$0.60	$62.48 million	$63.15 million
7/24/2025	Q2 2025	NVCR NovoCure	-$0.39	-$0.36	+$0.03	-$0.36	$153.87 million	$158.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYE National Vision	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.83%	N/A	38.83%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Latest RXST, NVCR, LMAT, and EYE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	LMAT LeMaitre Vascular	quarterly	$0.20	0.9%	8/21/2025	8/21/2025	9/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYE National Vision	0.30	0.52	0.31
LMAT LeMaitre Vascular	0.46	13.96	11.74
NVCR NovoCure	0.28	1.45	1.39
RXST RxSight	N/A	13.93	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYE National Vision	N/A
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
EYE National Vision	2.70%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	5.52%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYE National Vision	13,411	79.20 million	77.06 million	Optionable
LMAT LeMaitre Vascular	490	22.64 million	20.49 million	Optionable
NVCR NovoCure	1,488	111.80 million	105.63 million	Optionable
RXST RxSight	220	40.92 million	37.00 million	Optionable

RXST, NVCR, LMAT, and EYE Headlines

Recent News About These Companies

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in RxSight, Inc. Lawsuit – RXST

August 14 at 4:38 PM | globenewswire.com

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit

August 14 at 4:10 PM | prnewswire.com

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages RxSight, Inc. ...

August 14 at 2:27 PM | gurufocus.com

RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 14 at 1:21 PM | gurufocus.com

RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 14 at 12:00 PM | prnewswire.com

Class Action Filed Against RxSight, Inc. (RXST) - September 22, 2025 Deadline to Join - Contact ...

August 14 at 9:18 AM | gurufocus.com

Class Action Filed Against RxSight, Inc. (RXST) - September 22, 2025 Deadline to Join - Contact The Gross Law Firm

August 14 at 8:45 AM | prnewswire.com

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of RxSight, Inc.(RXST) Shareholders

August 13 at 4:40 PM | globenewswire.com

RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 13 at 4:00 PM | globenewswire.com

Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd

August 13 at 3:23 PM | globenewswire.com

RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 13 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 13 at 10:27 AM | globenewswire.com

RXSIGHT STOCK: Lose Money on Your RxSight, Inc. (NASDAQ:RXST) Investment? Contact BFA Law before the September 22 Legal Deadline

August 13 at 8:33 AM | globenewswire.com

RxSight’s Earnings Call: Mixed Results Amid Growth and Challenges

August 13 at 2:54 AM | msn.com

Investors Who Lost Money on RxSight, Inc. (RXST) Should Contact Levi & Korsinsky About Pending Class Action - RXST

August 12 at 8:53 PM | theglobeandmail.com

RXST INVESTOR NOTICE: RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

August 12 at 4:00 PM | prnewswire.com

RxSight, Inc. (NASDAQ:RXST) Q2 2025 Earnings Call Transcript

August 12 at 3:51 PM | msn.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

August 12 at 12:44 PM | globenewswire.com

RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST

August 12 at 9:00 AM | prnewswire.com

Class Action Filed Against RxSight, Inc. (RXST) Seeking Recovery for Investors - Contact Levi & Korsinsky

August 12 at 6:58 AM | theglobeandmail.com

RxSight (NASDAQ:RXST) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST, NVCR, LMAT, and EYE Company Descriptions

National Vision NASDAQ:EYE

$22.95 -0.27 (-1.16%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$23.09 +0.14 (+0.61%)

As of 08/14/2025 06:00 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

LeMaitre Vascular NASDAQ:LMAT

$95.81 +0.66 (+0.69%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$95.78 -0.03 (-0.03%)

As of 08/14/2025 05:52 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$11.59 -0.03 (-0.26%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$11.51 -0.08 (-0.69%)

As of 08/14/2025 07:53 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

RxSight NASDAQ:RXST

$8.22 -0.09 (-1.08%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$8.32 +0.10 (+1.27%)

As of 08/14/2025 06:12 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time